Dividend Shields: Top 5 Income Stocks
Market optimism has waned as investors weighed mixed data, Fed guidance, and sector-specific risks after the S&P 500 hit eight record highs in September. Strong GDP and jobs data have tempered rate cu...
Fiscal Year: January - December
Gilead Sciences, Inc. (GILD), listed on the NASDAQ, has a market capitalization of $. As of Oct 04, 2025, the stock is trading at $112.69 per share, offering investors a clear view of its current market value. Gilead Sciences, Inc. is a prominent player in the industry sector, attracting both institutional and retail investors due to its performance and potential.
With a P/E ratio of 22.49, investors can assess the stock's valuation in comparison to its earnings. A P/E ratio is a crucial indicator for value investors, showing whether the stock is over or undervalued relative to its current earnings. Gilead Sciences, Inc. also offers a dividend yield of 2.8%, making it an attractive option for income-focused investors who seek regular dividends.
Our Discounted Cash Flow (DCF) analysis reveals that Gilead Sciences, Inc. (GILD) may be undervalued compared to its intrinsic worth. However, to see the exact DCF fair value, please Login or Upgrade for access.
The proprietary SS Score for Gilead Sciences, Inc. is a unique metric that analyzes the company's financial health and growth potential. The score takes into account critical factors such as revenue growth, net income, free cash flow (FCF) compound annual growth rate (CAGR), the trend of shares outstanding, and the debt-to-FCF ratio. This helps investors to make a more informed decision, as an undervalued stock might still have poor financial fundamentals.
To view the detailed SS Score for Gilead Sciences, Inc., Login or Upgrade for access.
The Price to Free Cash Flow (P/FCF) ratio for Gilead Sciences, Inc. is 14.92, offering insights into how much investors are paying for the company's free cash flow. A lower P/FCF ratio typically suggests that the stock is undervalued, while a higher ratio may indicate overvaluation.
In summary, Gilead Sciences, Inc. (GILD) has shown consistent financial performance, as illustrated by the financial charts above, which track its revenue growth, net income, free cash flow, and shares outstanding over the past several years. These metrics provide investors with key insights into the company's past and projected future performance. Investors should use the SS Score alongside the DCF Fair Value to make better-informed decisions about whether to buy or hold the stock.
*This analysis is for informational purposes only and does not constitute investment advice. Always read the company's 10-K filings and do your own research before making any investment decisions.
Whether Gilead Sciences, Inc. (GILD) is a good stock to buy depends on various factors, including its financial health, market conditions, and your investment strategy. Our analysis indicates that the stock may be undervalued compared to its intrinsic value. However, it is important to assess the SS Score and review the company's fundamentals before making any investment decisions.
The fair value of Gilead Sciences, Inc. (GILD) is determined through our Discounted Cash Flow (DCF) analysis. This value represents the intrinsic worth of the stock based on its expected future cash flows. To view the specific fair value, consider subscribing to our service for complete access.
The SS Score is a proprietary financial quality metric that assesses factors such as revenue growth, net income, free cash flow growth, and debt levels. It helps investors evaluate the overall financial health of Gilead Sciences, Inc.. To access the full SS Score, consider upgrading your subscription.
Gilead Sciences, Inc. is a significant player in the industry sector, with a market capitalization of $ and a competitive P/E ratio of 22.49. Investors should compare these metrics with industry peers to gauge whether Gilead Sciences, Inc. is outperforming or underperforming within its sector.
Market optimism has waned as investors weighed mixed data, Fed guidance, and sector-specific risks after the S&P 500 hit eight record highs in September. Strong GDP and jobs data have tempered rate cu...
Hanmi and HHP will grant Gilead an exclusive license to Encequidar and provide access to drug supply. SEOUL, South Korea , Sept.
Courtney Breen, Bernstein senior analyst, joins 'The Exchange' to discuss the companies exempt from pharma tariffs, the country's with existing trade deals and much more.
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that it has committed more than $6.5 million in grant funding toward strengthening science, technology, engin...
Gilead Sciences is upgraded to 'Buy' as YEZTUGO's FDA approval strengthens its dominant HIV franchise and long-term outlook. GILD's valuation remains attractive, with a P/E of 14.74 and significant up...
SHANGHAI, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Fangzhou Inc. ("Fangzhou" or the "Company") (06086.HK), a leader in AI-driven Internet healthcare solutions, received the “Excellence Award” at Gilead Scie...
Gilead Sciences, Inc. (NASDAQ:GILD) Baird Global Healthcare Conference 2025 September 10, 2025 11:25 AM EDT Company Participants Cindy Perettie - Executive Vice President of Kite Conference Call Part...
Gilead Sciences, Inc. (NASDAQ:GILD) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 10:45 AM EDT Company Participants Daniel O'Day - Chairman & CEO Johanna Mercier - Chief C...
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced a partnership with the U.S. State Department and the United States President's Emergency Plan for AIDS Relief...
The U.S. State Department announced a plan on Thursday to bring Gilead Sciences Inc's drug lenacapavir to market "at cost" in high-burden HIV countries in an effort to reach 2 million people over thre...
Gilead Sciences, Inc. (NASDAQ:GILD) Wells Fargo 20th Annual Healthcare Conference 2025 September 4, 2025 11:00 AM EDT Company Participants Andrew Dickinson - Chief Financial Officer Conference Call P...
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the launch of Choose U™, a new campaign that spotlights the multifaceted experiences of people living with HI...
Gilead Sciences, Inc. (NASDAQ:GILD) Cantor Global Healthcare Conference 2025 September 3, 2025 11:30 AM EDT Company Participants Dietmar Berger - Chief Medical Officer Conference Call Participants Ca...
Global drugmakers are scrambling to shore up their U.S. manufacturing capacity and domestic inventory as the Trump administration weighs hefty tariffs on pharmaceutical imports into the country.
Gilead Sciences said on Wednesday it has started work on a new pharmaceutical development and manufacturing hub at its headquarters in Foster City, California, as part of its planned $32 billion inves...
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences (Nasdaq: GILD) today celebrates the groundbreaking of its new Pharmaceutical Development and Manufacturing (PDM) Technical Development Center (NTD...
Despite retail investors' cautious attitude toward Gilead Sciences, it once again beat analysts' expectations by a wide margin. In my estimation, Gilead's main star remains Biktarvy, which leaves comp...
The European Commission has granted marketing authorization for Gilead Sciences' twice-yearly injection for preventing HIV infection, the company said on Tuesday.
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission (EC) has granted marketing authorization for Yeytuo® (lenacapavir)—the company's...
Gilead Sciences' unit Kite Pharma said on Thursday it will acquire privately-held biotech firm Interius BioTherapeutics for $350 million in cash to advance CAR T-cell cancer therapies that are deliver...
CVS Health Inc. CVS said it will not add Gilead Sciences Inc.'s GILD new HIV prevention drug Yeztugo to its commercial plans.
SANTA MONICA, Calif. & PHILADELPHIA--(BUSINESS WIRE)--Kite has entered into a definitive agreement to acquire Interius BioTherapeutics, a privately held company developing in vivo CAR therapeutics.
Gilead Sciences remains a long-term Buy due to solid quarterly results, raised guidance, and continued strength in its HIV portfolio, especially Biktarvy. The recent launch of Yeztugo and a robust HIV...
CVS Health , which runs the largest U.S. pharmacy benefit manager, will not add Gilead Sciences' new HIV prevention drug to its commercial plans for now, a spokesperson told Reuters, despite the medic...
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #Earnings--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences: Cantor Global Healthc...
Below estimates were sourced from SimplyWallSt and are intended for educational purposes only as a baseline for the analysis.
Year | FCF Estimate | % | # Analysts |
---|---|---|---|
2025 | 11.28B | 9.47% | Est @9.5% |
2026 | 12.26B | 8.65% | Analyst x6 |
2027 | 13.18B | 7.51% | Analyst x5 |
2028 | 14.67B | 11.31% | Analyst x5 |
2029 | 15.49B | 5.64% | Analyst x5 |
2030 | 16.01B | 3.35% | Est @3.3% |
2031 | 16.50B | 3.03% | Est @3.0% |
2032 | 16.96B | 2.81% | Est @2.8% |
2033 | 17.41B | 2.66% | Est @2.7% |
2034 | 17.83B | 2.39% | Est @2.4% |
Below are the FCF estimates with the discount factor and the calculated present value with the terminal value that led the results above.
Year | FCF | Discount Factor | PV of Future FCF |
---|---|---|---|
2023A | 7.42B | 1.00 | 7.42B |
2024A | 10.31B | 1.00 | 10.31B |
2025E | 11.28B | 1.08 | 10.48B |
2026E | 12.26B | 1.16 | 10.57B |
2027E | 13.18B | 1.25 | 10.55B |
2028E | 14.67B | 1.34 | 10.91B |
2029E | 15.49B | 1.45 | 10.70B |
2030E | 16.01B | 1.56 | 10.27B |
2031E | 16.50B | 1.68 | 9.82B |
2032E | 16.96B | 1.81 | 9.38B |
2033E | 17.41B | 1.95 | 8.94B |
2034E | 17.83B | 2.10 | 8.50B |
Terminal | 352.23B | 2.10 | 167.94B |
The information given by Studying Stocks and provided in the web and/or mobile applications (Platforms) is only factual information and should not be considered financial advice.
Any information contained in this website has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
When creating an account, you acknowledge that you are:
We retain the right to cancel your account for any reason, or refuse your account creation request.
The information on our Platforms is not comprehensive and is intended to provide a summary of the subject matter covered. While we use all reasonable attempts to ensure the accuracy and completeness of the data and information on our Platforms, to the extent permitted by law, we make no warranty regarding the information on these Platforms. You should monitor any changes to the information contained on these Platforms.
Furthermore we make no commitments in regards to the minimum amount of uptime that our platforms will maintain, although we will make ever reasonable attempt to ensure that the platforms are operational. Therefore, any reference of "latest", "current" and related words about the financial data presented here may not be up to date with the financial markets or represent reality of the information.
We are not liable to you or anyone else if interference with or damage to your computer systems occurs in connection with the use of these Platforms or a linked website. You must take your own precautions to ensure that whatever you select for your use from our Platforms is free of viruses or anything else (such as worms or Trojan horses) that may interfere with or damage the operations of your computer systems.
We may, from time to time and without notice, change or add to the Platforms (including the Terms) or the information, products or services described in it. However, we do not undertake to keep the Platforms updated. We are not liable to you or anyone else if errors occur in the information or the Platforms is not up-to-date.
Our Platforms may contain links to websites operated by third parties. Those links are provided for convenience and may not remain current or be maintained. Unless expressly stated otherwise, we do not endorse and are not responsible for the content on those linked websites and have no control over or rights in those linked websites.
These Platforms are for your personal, non-commercial use only. You may not modify, copy, distribute, transmit, display, perform, reproduce, publish, license, commercially exploit, create derivative works from, transfer, or sell any Content, software, products or services contained within these Platforms. You may not use these Platforms, or any of its Content, to further any commercial purpose, including any advertising or advertising revenue generation activity on your own website.
You must not do any act that we would deem to be inappropriate, is unlawful or is prohibited by any laws applicable to these Platforms, including but not limited to:
If we allow you to post any information to our Platforms, we have the right to take down this information at our sole discretion and without notice.
To the maximum extent permitted by law, we make no warranties or representations about these Platforms or the Content, including but not limited to warranties or representations that they will be complete, accurate or up-to-date, that access will be uninterrupted or error-free or free from viruses, or that these Platforms will be secure.
We reserve the right to restrict, suspend or terminate without notice your access to these Platforms, any Content, or any feature of these Platforms at any time without notice and we will not be responsible for any loss, cost, damage or liability that may arise as a result.
To the maximum extent permitted by law, in no event shall we be liable for any direct and indirect loss, damage or expense – irrespective of the manner in which it occurs – which may be suffered due to your use of our Platforms and/or the information or materials contained on it, or as a result of the inaccessibility of these Platforms and/or the fact that certain information or materials contained on it are incorrect, incomplete or not up-to-date.
This website utilises cookies. If you do not have cookies enabled in your web browser some functions of the site may not work as intended.